Phase II study of 5-azacytidine in sarcomas of bone.
Eight patients with osteogenic sarcoma and seven patients with Ewing's sarcoma, all with advanced metastatic disease refractory to conventional therapy, were treated with 5-azacytidine (NSC-102816) intravenously at a dosage of 150 mg/m2 in three divided doses daily X 5 days. The courses were repeated q 4 weeks and the dosage was escalated to 200 mg/m2/day, as tolerated. Fourteen patients were evaluable for response. Major toxicities wee hematologic and gastrointestinal. 5-azacytidine had no demonstrable antitumor activity.